Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
Biomater Sci ; 2024 Jun 12.
Article En | MEDLINE | ID: mdl-38864476

Biomaterials are used as scaffolds in bone regeneration to facilitate the restoration of bone tissues. The local immune microenvironment affects bone repair but the role of immune response in biomaterial-facilitated osteogenesis has been largely overlooked and it presents a major knowledge gap in the field. Nanomaterials that can modulate M1 to M2 macrophage polarization and, thus, promote bone repair are known. This study investigates a novel approach to accelerate bone healing by using acemannan coated, cobalt-doped biphasic calcium phosphate nanoparticles to promote osteogenesis and modulate macrophage polarization to provide a prohealing microenvironment for bone regeneration. Different concentrations of cobalt were doped in biphasic calcium phosphate nanoparticles, which were further coated with acemannan polymer and characterized. The nanoparticles showed >90% cell viability and enhanced cell proliferation along with osteogenic differentiation as demonstrated by the enhanced alkaline phosphatase activity and osteogenic calcium deposition. The morphology of MC3T3-E1 cells remained unchanged even after treatment with nanoparticles. Acemannan coated nanoparticles were also able to decrease the expression of M1 markers, iNOS, and CD68 and enhance the expression of M2 markers, CD206, CD163, and Arg-1 as indicated by RT-qPCR, flow cytometry, and ICC studies. The findings show that acemannan coated nanoparticles can create a supportive immune milieu by inducing and promoting the release of osteogenic markers, and by causing a reduction in inflammatory markers, thus helping in efficient bone regeneration. As per our knowledge, this is the first study showing the combined effect of acemannan and cobalt for bone regeneration using immunomodulation. The work presents a novel approach for enhancing osteogenesis and macrophage polarization, thus, offering a potent strategy for effective bone regeneration.

2.
Adv Protein Chem Struct Biol ; 135: 343-395, 2023.
Article En | MEDLINE | ID: mdl-37061337

Cancer, a vicious clinical burden that potentiates maximum fatality for humankind, arises due to unregulated excessive cell division and proliferation through an eccentric expression of cell cycle regulator proteins. A set of evolutionarily conserved machinery controls the cell cycle in an extremely precise manner so that a cell that went through the cycle can produce a genetically identical copy. To achieve perfection, several checkpoints were placed in the cycle for surveillance; so, errors during the division were rectified by the repair strategies. However, irreparable damage leads to exit from the cell cycle and induces programmed cell death. In comparison to a normal cell, cancer cells facilitate the constitutive activation of many dormant proteins and impede negative regulators of the checkpoint. Extensive studies in the last few decades on cell division and proliferation of cancer cells elucidate the molecular mechanism of the cell-cycle regulators that are often targeted for the development of anti-cancer therapy. Each phase of the cell cycle has been regulated by a unique set of proteins including master regulators Cyclins, and CDKs, along with the accessory proteins such as CKI, Cdc25, error-responsive proteins, and various kinase proteins mainly WEE1 kinases, Polo-like kinases, and Aurora kinases that control cell division. Here in this chapter, we have analytically discussed the role of cell cycle regulators and proliferation factors in cancer progression and the rationale of using various cell cycle-targeting drug molecules as anti-cancer therapy.


Antineoplastic Agents , Neoplasms , Humans , Cell Cycle , Cell Division , Neoplasms/drug therapy , Neoplasms/genetics , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Cyclin-Dependent Kinases , Cell Proliferation
3.
Mater Today Proc ; 89: 24-29, 2023 Sep 05.
Article En | MEDLINE | ID: mdl-38590583

Studies have reported challenges of debonding of dental zirconia crowns to from luting cement and prepared teeth. The aim of the study was to explore the application of dental glazing systems for enhancing the bonding of zirconia dental ceramics to luting resin cement. Commercial glaze powder and liquid (Vita Akzent) and experimental mica-based glaze powders were used for the study. X-ray diffraction analysis of the glaze powders (XRD) and Fourier Transform InfraRed Spectroscopy (FTIR) was done on the glaze liquid. Sandblasted sintered dental zirconia (Katana, Noritake) were the control samples. Glazed zirconia samples were coated with commercial glaze and experimental glaze powders which were further etched with 5% hydrofluoric acid. Shear bond strengths of sandblasted and glazed zirconia samples to resin composites were evaluated. XRD of commercial and experimental glaze powders revealed a broad peak confirming the amorphous nature of glass and FTIR analysis of the glaze liquid revealed symmetrical stretching (CH2-CH3) of the alcohol group indicating a mixture of iso-butane and ethanol. Glazed and etched zirconia showed significantly higher shear bond strength to resin cement compared to sand-blasted zirconia. The study confirms the glassy nature of dental glaze powders and the presence of ethanol-based mixtures in the commercial glaze liquid. Glazing systems have the potential to be explored for enhancing the bonding of non-etchable zirconia ceramics to resin cement and tooth substrates.

4.
Life Sci ; 294: 120334, 2022 Apr 01.
Article En | MEDLINE | ID: mdl-35065161

AIMS: Imidazo[1,2-a]pyridine-based analogues have recently gained significant interest because of their wide spectrum of biological activities including anti-cancer potential, however the development of targeted therapeutic candidates against non-small cell lung cancer (NSCLC) is of utmost need due to its high prevalence and poor prognosis. Herein, we have aimed to synthesized novel imidazo [1,2-a] pyridine derivatives (IMPA) by coupling with 2-amino-4H-pyran to enhance bioactivity against NSCLC. MAIN METHODS: We have designed and synthesized a series of fifteen novel imidazo [1,2-a] pyridine derivatives through molecular hybridization and studied their anti-cancer activity against in-vitro lung adenocarcinoma and 3D multicellular lung tumor spheroids. KEY FINDINGS: IMPA-2, IMPA-5, IMPA-6, IMPA-8, and IMPA-12 markedly induced cytotoxicity by notably increased NADPH oxidase (NOX) activity, which results in the induction of ROS-mediated apoptosis in A549 lung cancer cells. It caused impairment of mitochondrial membrane potential by increasing pro-apoptotic BAX, and BAK1 expressions, and decreasing anti-apoptotic BCL2 expression, along with the induction of caspase-9/3 activation, however, these attributes were compromised in presence of N-acetyl-L-cysteine (NAC), a free radical scavenger. Increased ROS production by IMPAs also promotes p53 mediated cell cycle arrest through the inactivation of p38MAPK. Reduction of tumor size in IMPAs-treated 3D multicellular lung tumor spheroids gave further validation. SIGNIFICANCE: Beside cytotoxicity, IMPAs also inhibit lung cancer cell invasion and migration, suggesting their applicability in metastatic lung cancer. Therefore, IMPA derivatives could be used as potential anti-cancer agents in treating non-small cell lung cancer.


Adenocarcinoma of Lung/pathology , Antineoplastic Agents/pharmacology , Carcinoma, Non-Small-Cell Lung/pathology , Cell Cycle Checkpoints , Lung Neoplasms/pathology , Oxidative Stress , Pyridines/pharmacology , Adenocarcinoma of Lung/drug therapy , Adenocarcinoma of Lung/metabolism , Antineoplastic Agents/chemistry , Apoptosis , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/metabolism , Cell Proliferation , Humans , Imidazoles/chemistry , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Membrane Potential, Mitochondrial , Pyridines/chemistry , Reactive Oxygen Species/metabolism , Tumor Cells, Cultured , p38 Mitogen-Activated Protein Kinases/genetics , p38 Mitogen-Activated Protein Kinases/metabolism
...